News  |  Business  

Why Amgen thinks Celgene’s Psoriasis drug Otezla is worth $13.4 Billion

By Bloomberg   |   30 August 2019   |   2:42 pm  
Amgen Inc. will pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp., which is shedding the asset in order to win antitrust regulators’ sign-off for its $74 billion merger with Bristol-Myers Squibb Co. Bloomberg's Kailey Leinz reports on "Balance of Power."
In this article:
asset

You may also like